Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study

30 September 2014
pfizer-logo-big

US pharma major Pfizer (NYSE: PFE) and Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with mogamulizumab in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors.

PF-05082566 is an investigational, fully humanized monoclonal antibody (MAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival. Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab suppresses some of the immune cells that shield the tumor from the immune system.

Companies to co-fund the study

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical